Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

Giusy Gentilcore, Gabriele Madonna, Nicola Mozzillo, Antoni Ribas, Antonio Cossu, Giuseppe Palmieri, Paolo A. Ascierto

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations.Methods: Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib.Results: Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations.Conclusion: These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.

Original languageEnglish
Article number17
JournalBMC Cancer
Volume13
DOIs
Publication statusPublished - 14 Jan 2013
Externally publishedYes

Fingerprint

Melanoma
Cell Line
Mutation
Therapeutics
dabrafenib
Western Blotting
Phosphorylation
Cell Proliferation
Growth
Genes
Neoplasms
Proteins

Keywords

  • BRAF inhibitor
  • Dabrafenib
  • Growth inhibition
  • Melanoma therapy

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Gentilcore, G., Madonna, G., Mozzillo, N., Ribas, A., Cossu, A., Palmieri, G., & Ascierto, P. A. (2013). Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations. BMC Cancer, 13, [17]. https://doi.org/10.1186/1471-2407-13-17

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations. / Gentilcore, Giusy; Madonna, Gabriele; Mozzillo, Nicola; Ribas, Antoni; Cossu, Antonio; Palmieri, Giuseppe; Ascierto, Paolo A.

In: BMC Cancer, Vol. 13, 17, 14.01.2013.

Research output: Contribution to journalArticle

Gentilcore, G, Madonna, G, Mozzillo, N, Ribas, A, Cossu, A, Palmieri, G & Ascierto, PA 2013, 'Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations', BMC Cancer, vol. 13, 17. https://doi.org/10.1186/1471-2407-13-17
Gentilcore, Giusy ; Madonna, Gabriele ; Mozzillo, Nicola ; Ribas, Antoni ; Cossu, Antonio ; Palmieri, Giuseppe ; Ascierto, Paolo A. / Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations. In: BMC Cancer. 2013 ; Vol. 13.
@article{dadc3b3958674c3e8ed92ede0c34e877,
title = "Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations",
abstract = "Background: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations.Methods: Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib.Results: Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations.Conclusion: These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.",
keywords = "BRAF inhibitor, Dabrafenib, Growth inhibition, Melanoma therapy",
author = "Giusy Gentilcore and Gabriele Madonna and Nicola Mozzillo and Antoni Ribas and Antonio Cossu and Giuseppe Palmieri and Ascierto, {Paolo A.}",
year = "2013",
month = "1",
day = "14",
doi = "10.1186/1471-2407-13-17",
language = "English",
volume = "13",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

AU - Gentilcore, Giusy

AU - Madonna, Gabriele

AU - Mozzillo, Nicola

AU - Ribas, Antoni

AU - Cossu, Antonio

AU - Palmieri, Giuseppe

AU - Ascierto, Paolo A.

PY - 2013/1/14

Y1 - 2013/1/14

N2 - Background: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations.Methods: Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib.Results: Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations.Conclusion: These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.

AB - Background: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations.Methods: Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib.Results: Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations.Conclusion: These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.

KW - BRAF inhibitor

KW - Dabrafenib

KW - Growth inhibition

KW - Melanoma therapy

UR - http://www.scopus.com/inward/record.url?scp=84872122524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872122524&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-13-17

DO - 10.1186/1471-2407-13-17

M3 - Article

VL - 13

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 17

ER -